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doi:10.1016/j.kjms.2012.02.014Abstract The study’s purposes are to identify patient characteristics, treatment response
and survival rate, and to describe the important prognostic factors for our patients with
extranodal head and neck lymphoma. Furthermore, no study has systemically discussed the
overall figure of this disease in Taiwan and we analyzed our data on this topic. A retrospective
review was performed for 86 patients with extranodal head and neck lymphoma, diagnosed in
Kaohsiung Medical University Hospital, between 1990 and 2007. We evaluated the medical
records and analyzed the possible factors affecting treatment outcomes, survival rate, and
free-from-disease (FFD) survival rate. Forty-nine male and 37 female patients were included
with a male:female ratio of 1.32：1. The most frequent histologic type was diffuse large B cell
lymphoma, accounting for 41.9% of the total. The most common primary site involved with
extranodal head and neck non-Hodgkin’s lymphoma was a tonsil with 27 cases (31.4%). Stage,
international prognostic index (IPI) score, B symptoms, lactate dehydrogenase (LDH) level, and
lymph node status significantly affected treatment response. The overall 5- and 10-year
survival rates were 68.0% and 57.8%, respectively. The FFD survival rate was 53.6% and
49.3% at 5 and 10 years, respectively. Factors including stage, lymph node status, LDH level,
and IPI score produced significant differences in both overall survival and FFD survival. Ourof Otolaryngology, Kaohsiung Medical University Hospital, No.100, Tzyou 1st Road, Kaohsiung 807,
com.tw (W.-R. Kuo).
vier Taiwan LLC. All rights reserved.
436 H.-S. Chi et al.analyzed information is similar to other previously presented studies. Stage, IPI score, B symp-
toms, LDH level, and neck nodal status can be used to evaluate the treatment outcomes. Neck
nodal status and stage are the two significant prognostic factors for overall survival.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.Introduction
Lymphoma can be classified as Hodgkin disease and non-
Hodgkin disease. Extranodal Hodgkin disease is rarely
present; however, about 25% of patients with non-Hodgkin
lymphoma (NHL) manifest extranodally [1], of whom 33%
have the primary site at the head and neck area [2].
Statistically, extranodal head and neck NHL represents
4e15% of NHL patients.
Extranodal head and neck NHL comprises a group of
various tumors with different histology, treatment response
and prognosis. Many series have reviewed the characteris-
tics of the disease worldwide; however, no article has
systemically discussed the overall figure of this topic in
Taiwan. Our retrospective study aims to identify patient
characteristics, treatment response and survival rate, as
well as to describe the important prognostic factors for
these patients.
Materials and methods
We used the lymphoma database in Kaoshiung Medical
University Hospital, Taiwan, to identify extranodal lymphoma
of the head and neck area from 1990 to 2007 (86 cases in
total). The charts of these patients were reviewed to record
gender, age at diagnosis, histologic type, grading, primary
site, treatment protocol and response, and survival time.
We also recorded the possible prognostic factors. The World
Health Organization Classification of Tumors of Hemato-
poietic and Lymphoid Tissues (fourth edition) was used to
classify and grade the tumors, along with the Ann Arbor
staging system. Overall survival and free-from-disease
(FFD) survival were calculated from time of diagnosis
until death and recurrence respectively, or until last
follow-up. Treatment response was classified into complete
response (100% resolution), partial response (50e100%
resolution), no response (<50% resolution), and progression
of disease (tumor enlarging after treatment). The interna-
tional prognostic index (IPI) is a clinical tool developed by
oncologists to aid in predicting the prognosis of patients
with aggressive NHL and we used this in our study. Statistics
with KaplaneMeier survival plots and the Cox regression
test was performed to evaluate survival rate and identify
possible significant factors in survival. The binomial test
was used to evaluate the predisposing factors affecting
treatment response.
Results
Of the 101 patients reviewed, 86 were included in the
study. Cases with incomplete data and lack of follow-up
were excluded. Patient and disease characteristics are
described in Table 1. The age at presentation ranged from 6to 89 years with a mean of 55 years and a peak in the
seventh decade. Forty-nine patients were male and 37
female, giving a male:female ratio of 1.32：1. The distri-
bution did not reveal a significant difference in gender. Of
the 86 patients, 13 cases (16.5%) had B symptoms (body
weight loss, fever and night sweating). Early stage (stages I
and II) accounts for 69 cases (80.2%) and late stage (stages
III and IV) for 17 cases (19.8%). Excluding the 13 unavailable
patients, the grading of tumors was classified into low,
intermediate and high, with numbers of 12, 59 and 2,
respectively. Metastasis of regional neck lymph nodes was
noted in 39 (45.3%) tumors. There were 17 individuals with
high-level lactate dehydrogenase (LDH), and 51 (75.0%)
within the normal range, according to the available data.
Patients with low IPI scores (0e1) represented 70.4% of the
total (n Z 50).
Table 1 also shows treatment modality including chemo-
therapy, surgery, radiotherapy, and combination therapy
with at least two kinds of therapies. Combination treat-
ment modality was performed in 33 tumors (41.8%) and
chemotherapy alone in 46 (58.2%). The doses of radio-
therapy ranged from 2400 cGy to 6840 cGy, with a median
of 4000 cGy. Common regimens of chemotherapy were
mainly based on cyclophosphamide, doxorubicin, vincris-
tine and prednisone (CHOP) with some variations. Sixty-
four patients were noted with complete response and 22
without. The complete response rates between various
subgroups, and tumor characteristics were evaluated by
the binomial test. Several factors which significantly
affected complete response are also described in this table.
As shown in Table 2, the most common primary site
involved by extranodal head and neck NHL was a tonsil,
with 27 cases (31.4%). Cases of the Waldeyer’s ring,
including tonsil, nasopharynx and tongue base, reached as
high as 50% (43 patients). The area of the sinus and nasal
cavity was the second most common site affected, with 14
cases (16.3%). The distribution of other sites is also shown.
The most frequent histologic type was diffuse large B
cell lymphoma, consisting of 41.9% of the total (n Z 36).
The second most common type was small lymphocytic
lymphoma (n Z 7; 8.1%) and all other types accounted for
43 cases (50%).
Live patients were followed for a median duration of
63.0 months (range: 2e187 months). Twenty-nine deaths
were recorded. The overall 5- and 10-year survival rates
were 68.0% and 57.8%, respectively (Fig. 1A). The FFD
survival rate was 53.6% and 49.3% at 5 and 10 years,
respectively (Fig. 1B). Among the 11 possible risk factors
affecting overall survival and FFD survival (Table 3), stage
(I þ II vs. III þ IV) (Figs. 2A and 2B), lymph node status
(normal vs. adenopathy) (Figs. 2C and 2D), LDH level
(normal vs. high level) (Figs. 2E and 2F), and IPI score ( 1
vs. > 1) (Figs. 2G and 2H) produced significant differences
in both overall survival and FFD survival using univariate
Table 1 Patient and disease characteristics, and complete response rate according to potential risk factors.
Characteristic Number of patients
available
Number (%) CR rate (%)
(total CR no.: 64)
p
Age (y)
60 86 48 (55.8) 72.9 0.72
>60 38 (44.2) 76.3
Sex
Males 86 49 (43.0) 75.5 0.79
Females 37 (57.0) 73.0
Primary site
Waldeyer’s ring (tonsil, nasopharynx,
and tongue base)
86 43 (50.0) 76.7 0.62
Others 43 (50.0) 72.1
Stage
I þ II (early stage) 86 69 (80.2) 79.7 0.023*
III þ IV (late stage) 17 (19.8) 52.9
Neck lymph node status
No adenopathy 86 47 (54.7) 83.0 0.046*
Adenopathy 39 (45.3) 64.1
Histology
Diffuse large B cell lymphoma 86 36 (41.9) 75.0 P Z 0.92
Others 50 (58.1) 74.0
Grade
Low 73 12 (16.4) 91.7 0.11
Intermediate þ high 61 (83.6) 71.2
B symptoms
Any symptoms 79 13 (16.5) 53.8 0.041*
No B symptoms 66 (83.5) 82.8
LDH level
Normal 68 51 (75.0) 84.3 <0.001*
High 17 (25.0) 35.3
Treatment modality
Chemotherapy alone 79 46 (58.2) 82.6 0.102
Combination treatment 33 (41.8) 66.7
IPI score
0 w 1 71 50 (70.4) 84.0 0.001*
2 w 4 21 (29.6) 42.9
* p < 0.05.
CR Z complete response; IPI Z international prognostic index; LDH Z lactate dehydrogenase.
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status (normal vs. adenopathy) and stage (I þ II vs. III þ IV)
were the two significant prognostic factors for overall
survival rate.Discussion
Many series have studied the various properties of extra-
nodal NHL of the head and neck worldwide. However, no
article has discussed the overall figure of this topic in
Taiwan. In our study, the clinicopathologic characteristics,
therapeutic protocol, treatment response and prognosis
were retrospectively reviewed and we tried to identify the
profile of the disease in Taiwan.The median age of the cases was 55 years. Several series
(55e57.5 years) have shown results which are consistent
with our data. We found the peak incidence to be in the
seventh decade, which is the same as found in other studies
[3,4]. Economoponlos et al. [5] and Shine et al. [6] reported
the peak to be in the sixth decade. There was no significant
difference in sex distribution, as was the case in other
studies [1,3,7,8]. However, two other studies found
a significant male predominance in incidence: Sasai et al.
[9] reported 68 males and 42 females; and Shima et al. [4]
presented 69 males and 45 females.
On viewing the primary site of the head and neck
extranodal lymphoma, tonsils were the most commonly
involved areas in our series (31.4% of the total), which
is consistent with other investigators [1e3,10]. Cases
Table 2 Numbers of patients according to primary sites.
Number (%)
Primary site
Tonsil 27 (31.4)
Sinus and nasal cavity 14 (16.3)
Tongue base 10 (11.6)
Thyroid 9 (10.5)
Orbit/conjunctiva 9 (10.5)
Nasopharynx 6 (7.0)
Salivary gland 6 (7.0)
Hard palate 2 (2.3)
Other sites undefined 3 (3.5)
Total 86 (100)
438 H.-S. Chi et al.occurring in paranasal sinus and nasal cavity accounted for
16.3% of our patients, and these regions were the second
most common primary site in the study. Several series
described the range to be from 12.5% to 16.7% [1,11,12]. As
expected, diffuse large B cell lymphoma was the most
frequent histologic type (41.9%; n Z 36) [3,9]. Only 16.5%
of patients had B symptoms in our study, while some
authors reported figures from 10% to 15% [3,13]. In general,
the incidence of B symptoms in the patients with NHL is
similar to our data.
There is no doubt that most extranodal NHLs of head and
neck are found in the early stage. For Hanna et al. [14], 75%
and 25% of patients were in the early (stages I þ II) and
advanced (stages IIIþ IV) stages, respectively, while Jacobs
et al. [12] found 66% of cases in the early stage, both of
which are similar to our results (80.2%).
Analysis of factors influencing treatment response and
survival rate require the adjustment of IPI in NHL (zero and
one factor vs. more than one factor) to identify possible
groups with a better treatment response and higher survival
rate. In one published study, the authors implied that the
modification of IPI may better reflect prognostic value
among low-risk patients [13].
The treatment modality of head and neck extranodal
NHL was influenced by many factors, which included theFigure 1. KaplaneMeier plots of (A) overall survivalclinical stage, institutional protocol, or health conditions of
patients. Thirty-six percent (n Z 28) of our patients
received radiotherapy and most also received additional
therapies (chemotherapy or surgery). Chemotherapy based
on CHOP may be aggressive for disease control and if
needed, additional therapy (including radiotherapy or
surgery) is considered to be the better treatment plan [12].
Some studies noted that the effect of radiotherapy with
chemotherapy was better than chemotherapy alone
[13,15]. In one review, although combination treatment
had no significant overall survival advantage, it was signif-
icantly associated with better disease-free survival [13].
Aviles et al. [15] concluded that, in cases of localized NHL
of head and neck, radiotherapy with chemotherapy
produced significantly better overall survival than chemo-
therapy alone. However, because of the small number of
our patients, we could not achieve the same results.
Some series have noted several adverse factors for
treatment response, such as old age, bulky lymph node,
higher IPI score, and advanced stage [13,16,17]. In our
study, using univariate analysis, we compared the
subgroups of 11 factors and found that advanced stage,
higher IPI scores, B symptoms, high levels of LDH, and the
presence of neck nodal adenopathy, with significance,
adversely affected treatment response with a lower
complete response rate. As a result, we can predict the
tumor response after therapeutic plan, using these factors.
The overall 5- and 10-year survival rates (68.0% and
57.8%, respectively) in our study were not significantly
different from these of other series. Economopoulos et al.
[5] reported 65% at 5-year overall survival rate. MacDermed
et al. [17] also demonstrated rates of 92% and 70% of 5- and
10-year overall survival, respectively. The FFD survival
rates of our patients at 5 and 10 years were 53.6% and
49.3%, respectively. Several investigators had similar
results [1,5,14,18].
There were some causes for the variation between the
studies, including the various complex classification system
of lymphomas, inter-institutional differences in thera-
peutic regimens (selection criteria of protocol, dosage or
treatment cycles), racial differences, and patient selection
(smaller sample size) [3].and (B) free-from-disease survival for all patients.
Table 3 Results of univariate and multivariate analysis on the 11 factors that may affect overall or free-from-disease survival rate.
Variable Overall survival FFD survival
Univariate p (HR; CI) Multivariate p (HR; CI) Univariate p (HR; CI) Multivariate p (HR; CI)
Age (60 y vs. >60 y) 0.910 ea 0.746 e
Sex (male vs. female) 0.525 e 0.286 e
Primary site (Waldeyer’s ring vs.
others)
0.966 e 0.491 e
Stage (I þ II vs. III þ IVe favoring
I þ II)
0.001* (0.261;
0.119 w 0.570)
0.045** (0.254;
0.067 w 0.968)
0.007* (0.394;
0.202 w 0.771)
NS
Neck lymph node status (normal
vs. adenopathye
favoring normal neck lymph
node)
0.009* (0.336;
0.149 w 0.760)
0.004** (0.267;
0.108 w 0.660)
0.033* (0.498;
0.262 w 0.946)
NS
Histology (DLBCL vs. others) 0.312 e 0.844 e
Grade (low vs.
intermediate þ high)
0.359 e 0.770 e
B symptoms (any symptoms vs.
none)
0.297 e 0.342 e
LDH level (normal vs. high
efavoring normal level)
0.005* (0.312;
0.139 w 0.704)
NS 0.027* (0.442;
0.214 w 0.911)
NS
Treatment modality
(chemotherapy vs.
combination therapy)
0.150 e 0.246 e
IPI score ( 1 vs. >1efavoring 1) 0.001* (0.270;
0.122 w 0.593)
NS 0.010* (0.402;
0.201 w 0.804)
NS
* p < 0.05 on univariate analysis.
** p < 0.05 on multivariate analysis.
CI Z confidence interval; DLBCL Z diffuse large B cell lymphoma; FFD Z free-from-disease; HR Z hazard ratio; IPI Z international prognostic index; LDH Z lactate dehydrogenase;
NS Z not significant.
a Not evaluated in multivariate analysis.
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Figure 2. KaplaneMeier plots of overall survival and free-from-disease survival by (A and B) stage, (C and D) neck lymph node
status, (E and F) LDH level, and (G and H) international prognostic index score.
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Head and neck extranodal lymphoma 441After comparing the subgroups of the 11 factors by the
use of univariate analysis, the data revealed that advanced
stage (p Z 0.007), higher IPI score (p Z 0.01), high LDH
level (p Z 0.027), and neck nodal diseases (p Z 0.033)
adversely affected overall survival and FFD survival, with
significance. Furthermore, multivariate analysis showed
that neck nodal status and stage were the two significant
prognostic factors for overall survival in our study. We have
reviewed several studies and only two articles evaluated
the influence of neck lymphadenopathy on survival
[13,19]:. Both articles concluded that regional nodes did
not predict overall survival. However, abnormal neck lymph
nodes were shown to have poor influence on prognosis in
our study. We consider that the different results may be
because of population selection. Subjects in the two
studies were specific subgroups of extranodal head and
neck lymphoma, but our patients were from the general
population of the disease. Therefore, neck nodal status can
be viewed as an independent index for prognosis. Patients
in the advanced stage had a worse survival rate. The effect
of stage has been emphasized repeatedly in many studies
and our data are in agreement [2,4,5,20].
In conclusion, we reviewed the general characteristics
of extranodal NHL of the head and neck and, to the best of
our knowledge, this is the first systemic analysis in Taiwan.
The information included here is similar to other previous
studies. Several factors, includung stage, IPI score, B
symptoms, LDH level, and neck nodal status, can be used to
evaluate the treatment response. Overall survival and FFD
survival can be evaluated with the prognostic effects of
tumor stage, IPI score, LDH level, and neck nodal status. In
particular, neck nodal status and stage are the two signifi-
cant prognostic factors for overall survival.
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